Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.
Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.
复制标题
DOI：
10.1186/s12916-016-0711-6
复制
发表时间：
2016-10-17
期刊：
影响因子：
9.3
通讯作者：
Ke Q
中科院分区：
文献类型：
--
作者：
Guo B;Cen H;Tan X;Ke Q
肿瘤相关巨噬细胞（TAM）在成人经典型霍奇金淋巴瘤（cHL）中的预后意义仍存在争议。在这里，我们报告了一项关于CD 68和CD 163浸润与成人cHL临床结局相关性的荟萃分析。2016年1月31日，在PubMed、Embase和Google Scholar中进行了全面检索，以识别相关文章。使用DerSimonian和Laird的固定效应或随机效应模型，将风险比（HR）或比值比（OR）和95%置信区间（CI）用作效应量估计值。确定了22项合格研究，共2959例患者。我们的分析表明，成人cHL肿瘤微环境中高密度的CD 68 + TAM预示着较差的总生存率（OS）。（HR：2.41; 95% CI，1.92-3.03），无进展生存期（PFS）较短（HR：1.78; 95% CI，1.45-2.18）和疾病特异性生存率差（HR：2.71; 95% CI，1.38-5.29）。成人cHL肿瘤微环境中高密度的CD 163 + TAM也预测OS较差（HR：2.75; 95% CI，1.58-4.78）和PFS较差（HR：1.66; 95% CI，1.22-2.27）。此外，我们证明了高密度的CD 68+或CD 163 + TAM与肿瘤细胞中EB病毒的存在相关（OR CD 68：3.13; 95% CI，2.02-4.84; OR CD 163：2.88; 95% CI，1.55-5.34）。高密度的CD 68+或CD 163 + TAM倾向于与更晚期的临床分期相关。（OR CD 68：1.25; 95% CI，0.93-1.67; OR CD 163：1.19; 95% CI，0.86-1.63），B症状（ORCD 68：1.35; 95% CI，0.90-2.01; ORCD 163：2.19; 95% CI，0.96-5.03），国际预后因素项目评分较高（ORCD 68：1.20; 95% CI，0.67-2.15; ORCD 163：2.00; 95% CI，0.92-4.35）和巨大病灶（ORCD 68：1.47; 95% CI，0.88-2.47; ORCD 163：1.19; 95% CI，0.72-1.96）。我们的分析表明，高密度的CD 68+或CD 163 + TAM是成人cHL不良结局的可靠预测因子。增加TAM应考虑到进一步改善预后分层和适当的治疗策略的规划。
The prognostic significance of tumor-associated macrophages (TAM) in adult classical Hodgkin lymphoma (cHL) remains controversial. Here, we report a meta-analysis of the association of CD68 and CD163 infiltration on the clinical outcome of adult cHL. A comprehensive search to identify relevant articles was performed in PubMed, Embase, and Google Scholar on January 31, 2016. Using the fixed effect or random effects model of DerSimonian and Laird, hazard ratios (HR) or odds ratios (OR) with 95 % confidence intervals (CIs) were used as the effect size estimate. Twenty-two eligible studies with a total of 2959 patients were identified. Our analysis indicated that a high density of CD68+ TAMs in the tumor microenvironment of adult cHL predicted poor overall survival (OS) (HR: 2.41; 95 % CI, 1.92–3.03), shorter progression-free survival (PFS) (HR: 1.78; 95 % CI, 1.45–2.18), and poor disease-specific survival (HR: 2.71; 95 % CI, 1.38–5.29). High density of CD163+ TAMs in the tumor microenvironment of adult cHL also predicted poor OS (HR: 2.75; 95 % CI, 1.58–4.78) and poor PFS (HR: 1.66; 95 % CI, 1.22–2.27). In addition, we demonstrated that a high density of either CD68+ or CD163+ TAMs was associated with the presence of Epstein-Barr virus in neoplastic cells (ORCD68: 3.13; 95 % CI, 2.02–4.84; ORCD163: 2.88; 95 % CI, 1.55–5.34). A high density of either CD68+ or CD163+ TAMs tend to be associated with a more advanced clinical stage (ORCD68: 1.25; 95 % CI, 0.93–1.67; OR CD163: 1.19; 95 % CI, 0.86–1.63), B-symptoms (ORCD68: 1.35; 95 % CI, 0.90–2.01; ORCD163: 2.19; 95 % CI, 0.96–5.03), higher International Prognostic Factors Project Score (ORCD68: 1.20; 95 % CI, 0.67–2.15; ORCD163: 2.00; 95 % CI, 0.92–4.35), and bulky disease (ORCD68: 1.47; 95 % CI, 0.88–2.47; ORCD163: 1.19; 95 % CI, 0.72–1.96). Our analyses suggest that a high density of either CD68+ or CD163+ TAMs is a robust predictor of adverse outcomes in adult cHL. Increased TAMs should be taken into account to further improve prognostic stratification and the planning of appropriate therapeutic strategies.
登录
查看更多内容
影响因子：
3.7
作者：
Koh YW;Park CS;Yoon DH;Suh C;Huh J
通讯作者：
Huh J
影响因子：
11.5
作者：
Hohaus, Stefan;Santangelo, Rosaria;Larocca, Luigi M.
通讯作者：
Larocca, Luigi M.
影响因子：
50.5
作者：
Azambuja, D.;Natkunam, Y.;Spector, N.
通讯作者：
Spector, N.
DOI：
10.3324/haematol.2010.031542
发表时间：
2011-02-01
期刊：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
影响因子：
--
作者：
Kamper, Peter;Bendix, Knud;d'Amore, Francesco
通讯作者：
d'Amore, Francesco
影响因子：
3.5
作者：
Klein, Jonathan L.;Nguyen, TuDung T.;Kreisel, Friederike
通讯作者：
Kreisel, Friederike